- Previous Close
111.95 - Open
112.88 - Bid 112.01 x 800
- Ask 112.65 x 900
- Day's Range
111.79 - 113.02 - 52 Week Range
94.73 - 148.15 - Volume
4,450,401 - Avg. Volume
4,267,398 - Market Cap (intraday)
499.241B - Beta (5Y Monthly) 0.15
- PE Ratio (TTM)
38.34 - EPS (TTM)
2.92 - Earnings Date Nov 6, 2024
- Forward Dividend & Yield 1.45 (1.29%)
- Ex-Dividend Date Aug 16, 2024
- 1y Target Est
142.92
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
www.novonordisk.com69,260
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: NVO
View MoreRelated Videos: NVO
Performance Overview: NVO
Trailing total returns as of 11/1/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NVO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NVO
View MoreValuation Measures
Market Cap
499.24B
Enterprise Value
498.42B
Trailing P/E
38.30
Forward P/E
27.93
PEG Ratio (5yr expected)
1.71
Price/Sales (ttm)
13.34
Price/Book (mrq)
30.41
Enterprise Value/Revenue
13.24
Enterprise Value/EBITDA
25.51
Financial Highlights
Profitability and Income Statement
Profit Margin
34.84%
Return on Assets (ttm)
22.80%
Return on Equity (ttm)
88.57%
Revenue (ttm)
258B
Net Income Avi to Common (ttm)
89.9B
Diluted EPS (ttm)
2.92
Balance Sheet and Cash Flow
Total Cash (mrq)
62.65B
Total Debt/Equity (mrq)
50.71%
Levered Free Cash Flow (ttm)
54.49B
Research Analysis: NVO
View MoreCompany Insights: NVO
NVO does not have Company Insights
Research Reports: NVO
View MoreGlobal Stocks Priced at Discount to U.S. Stocks
As worldwide markets are challenged in an environment of higher interest rates, conflict in the Middle East, and the lingering battle between Russia and Ukraine, one thing has not changed: U.S. stocks are more expensive than global stocks. And with the large run-up in stock prices in late 2023 and the first half of 2024, U.S. stocks are even more expensive. Consider P/E ratios. The trailing P/E ratio on the S&P 500 is 28, above the global average of 14 and well above the 6-12 average P/Es for emerging markets stocks. A review of yields tells a similar story. The current dividend yield for the S&P 500 is 1.2%, versus the global average of 2.8% and Asian, Australian and Latin American yields of 3%-6%. The foreign region that does not completely fit the pattern is the Middle East. The average P/E on a Saudi Arabian stock is a relatively high 17. This can be attributed to high oil prices. Taking a step back, one reason investors generally are willing to pay a higher price for North American securities is the transparency of the U.S. financial system as well as the liquidity of U.S. markets. What's more, global returns can be volatile across individual countries, given currency, security, political, and geopolitical risks. Indeed, U.S. stocks (ETF SPY) have outperformed EAFE (ETF EFA) over the past year as well as over the past five years. Even so, we recommend that growth investors have approximately 5%-10% of their equity allocations in international stocks to take advantage of the value, and we have been adding global stocks to our Universe of Coverage.
Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
In this edition, playing the long game on commercial turbine engines; making the case for integrated oils despite the headlines; watching where Prudential tilts; and Nike, Novo Nordisk, and Zhejiang Supor.
Novo Nordisk: Disappointing Early Data for Novel Oral Obesity Drug
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
RatingPrice TargetNovo Nordisk: Disappointing Early Data for Novel Oral Obesity Drug
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
RatingPrice Target